mTOR Complex 2 Is Required for the Development of Prostate Cancer Induced by Pten Loss in Mice
Top Cited Papers
- 1 February 2009
- journal article
- research article
- Published by Elsevier in Cancer Cell
- Vol. 15 (2) , 148-159
- https://doi.org/10.1016/j.ccr.2008.12.017
Abstract
No abstract availableKeywords
Funding Information
- Howard Hughes Medical Institute
- W. M. Keck Foundation
- Damon Runyon Cancer Research Foundation
- Leukemia and Lymphoma Society
- National Institutes of Health (K99 CA1296613-01A1, R01 AI04389, R01 CA103866, R01 CA107166)
This publication has 56 references indexed in Scilit:
- The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase CThe EMBO Journal, 2008
- Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signallingThe EMBO Journal, 2008
- Tenets of PTEN Tumor SuppressionCell, 2008
- AKT/PKB Signaling: Navigating DownstreamCell, 2007
- Re-evaluating AKT regulation: role of TOR complex 2 in tissue growthGenes & Development, 2007
- Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycinCancer Cell, 2006
- The deficiency ofAkt1is sufficient to suppress tumor development inPten+/−miceGenes & Development, 2006
- mTOR Interacts with Raptor to Form a Nutrient-Sensitive Complex that Signals to the Cell Growth MachineryCell, 2002
- Mutation ofPten/Mmac1in mice causes neoplasia in multiple organ systemsProceedings of the National Academy of Sciences, 1999
- High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in miceCurrent Biology, 1998